1990-2017年全球、区域及国家类风湿关节炎负担:GBD 2017系统分析
该研究基于GBD 2017数据,系统分析195个国家1990-2017年类风湿关节炎的患病率、发病率和伤残调整寿命年(DALY)。2017年全球年龄标化患病率和发病率分别为246.6/10万和14.9/10万,较1990年分别上升7.4%和8.2%;年龄标化DALY率为43.3/10万,较1990年下降3.6%。
要点
- 2017年全球RA年龄标化患病率246.6/10万,发病率14.9/10万,较1990年分别上升7.4%和8.2%。
- 年龄标化DALY率43.3/10万,较1990年下降3.6%,但1990-2012年下降后至2017年回升。
- 女性年龄标化患病率和DALY率高于男性,患病率峰值在70-74岁(女)和75-79岁(男)。
核心结论
- RA是重大全球公共卫生挑战,年龄标化患病率和发病率上升,早期识别和治疗对减少负担至关重要。
研究设计与样本
- 基于GBD 2017研究,对195个国家1990-2017年RA的死亡率与发病率数据进行系统分析,建模估计患病率、发病率和DALY。
主要发现
- 2017年全球年龄标化患病率为246.6(95% UI 222.4-270.8)/10万,年发病率为14.9(95% UI 13.3-16.4)/10万。
- 2017年年龄标化DALY率为43.3(95% UI 33.0-54.5)/10万,较1990年下降3.6%(95% UI -9.7至0.3)。
- 英国2017年年龄标化患病率(471.8(95% UI 428.9-514.9))和发病率(27.5(95% UI 24.7-30.0))最高。
- 1990-2017年加拿大、巴拉圭和危地马拉年龄标化患病率增幅最大(54.7%(95% UI 49.2-59.7)、41.8%(95% UI 35.0-48.6)、37.0%(95% UI 30.9-43.9))。
- 年龄标化DALY率与SDI呈非线性关联;全球年龄标化DALY率1990-2012年下降,随后5年上升并超过预期水平。
临床怎么用
- 关注女性及高龄人群的RA早期识别与治疗,以降低疾病负担。
- 需改善健康数据质量以更好监测疾病负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide the level and trends of prevalence, incidence and disability adjusted life years (DALYs) for rheumatoid arthritis (RA) in 195 countries from 1990 to 2017 by age, sex, Socio-demographic Index (SDI; a composite of sociodemographic factors) and Healthcare Access and Quality (an indicator of health system performance) Index. METHODS: Data from the Global Burden of Diseases, Injuries, and Risk Factors study (GBD) 2017 were used. GBD 2017 modelled the burden of RA for 195 countries from 1990 to 2017, through a systematic analysis of mortality and morbidity data to estimate prevalence, incidence and DALYs. All estimates were presented as counts and age-standardised rates per 100 000 population, with uncertainty intervals (UIs). RESULTS: Globally, the age-standardised point prevalence and annual incidence rates of RA were 246.6 (95% UI 222.4 to 270.8) and 14.9 (95% UI 13.3 to 16.4) in 2017, which increased by 7.4% (95% UI 5.3 to 9.4) and 8.2% (95% UI 5.9 to 10.5) from 1990, respectively. However, the age-standardised rate of RA DALYs per 100 000 population was 43.3 (95% UI 33.0 to 54.5) in 2017, which was a 3.6% (95% UI -9.7 to 0.3) decrease from the 1990 rate. The age-standardised prevalence and DALY rates increased with age and were higher in females; the rates peaked at 70-74 and 75-79 age groups for females and males, respectively. A non-linear association was found between age-standardised DALY rate and SDI. The global age-standardised DALY rate decreased from 1990 to 2012 but then increased and reached higher than expected levels in the following 5 years to 2017. The UK had the highest age-standardised prevalence rate (471.8 (95% UI 428.9 to 514.9)) and age-standardised incidence rate (27.5 (95% UI 24.7 to 30.0)) in 2017. Canada, Paraguay and Guatemala showed the largest increases in age-standardised prevalence rates (54.7% (95% UI 49.2 to 59.7), 41.8% (95% UI 35.0 to 48.6) and 37.0% (95% UI 30.9 to 43.9), respectively) and age-standardised incidence rates (48.2% (95% UI 41.5 to 55.1), 43.6% (95% UI 36.6 to 50.7) and 36.8% (95% UI 30.4 to 44.3), respectively) between 1990 and 2017. CONCLUSIONS: RA is a major global public health challenge. The age-standardised prevalence and incidence rates are increasing, especially in countries such as Canada, Paraguay and Guatemala. Early identification and treatment of RA is vital especially among females, in order to reduce the ongoing burden of this condition. The quality of health data needs to be improved for better monitoring of disease burden.
引用
- Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019. PMID: 31511227. doi:10.1136/annrheumdis-2019-215920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。